ANJESO Drug Insight and Market Forecast – 2032

ANJESO Drug Insight and Market Forecast – 2032

“ANJESO Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ANJESO for Postoperative Pain in the United States. A detailed picture of the ANJESO for Postoperative Pain in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the ANJESO for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ANJESO market forecast, analysis for Postoperative Pain in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative Pain.

Drug Summary

ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. ANJESO (meloxicam) injection was approved by the US Food and Drug Administration (FDA) in February 2020 for use in adults to manage moderate to severe pain, alone or in combination with non-NSAID analgesics. Because of the delayed onset of analgesia, ANJESO alone is not recommended for use when a rapid onset of analgesia is required.

Meloxicam is a long-acting NSAID with preferential COX-2 inhibition that possesses anti-inflammatory, analgesic, and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase (COX) and subsequent reduction in prostaglandin biosynthesis. Boehringer Ingelheim Pharmaceuticals, Inc. have marketed meloxicam since the 1990s as an oral agent, Mobic. It is used for the treatment of symptoms of osteoarthritis and rheumatoid arthritis.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the ANJESO description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.

Elaborated details on ANJESO regulatory milestones and other development activities have been provided in this report.

The report also highlights the ANJESO research and development activity in Postoperative Pain in detail across the United States.

The report also covers the patents information with expiry timeline around ANJESO.

The report contains forecasted sales of ANJESO for Postoperative Pain till 2032.

Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.

The report also features the SWOT analysis with analyst views for ANJESO in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ANJESO Analytical Perspective by DelveInsight

In-depth ANJESO Market Assessment

This report provides a detailed market assessment of ANJESO in Postoperative Pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

ANJESO Clinical Assessment

The report provides the clinical trials information of ANJESO in Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ANJESO dominance.

Other emerging products for Postoperative Pain are expected to give tough market competition to ANJESO and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ANJESO in Postoperative Pain.

Our in-depth analysis of the forecasted sales data of ANJESO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ANJESO in Postoperative Pain.

Key Questions

What is the product type, route of administration and mechanism of action of ANJESO?

What is the clinical trial status of the study related to ANJESO in Postoperative Pain and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ANJESO development?

What are the key designations that have been granted to ANJESO for Postoperative Pain?

What is the forecasted market scenario of ANJESO for Postoperative Pain?

What are the forecasted sales of ANJESO in the United States?

What are the other emerging products available in Postoperative Pain and how are they giving competition to ANJESO for Postoperative Pain?

Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?